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5-Lipoxygenase-activating protein rescues activity of
5-lipoxygenase mutations that delay nuclear membrane
association and disrupt product formation
Jana Gerstmeier,* Marcia E. Newcomer,† Sophie Dennhardt,* Erik Romp,* Jana Fischer,*
Oliver Werz,* and Ulrike Garscha*,1
*Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-
University Jena, Germany; and †Department of Biological Sciences, Louisiana State University, Baton Rouge,
Louisiana, USA
ABSTRACT Leukotrienes (LTs) are proinflammatory
lipid mediators formed from arachidonic acid in a 2-step
reaction catalyzed by 5-lipoxygenase (5-LOX) requiring the
formationof5-HPETE[5(S)-hydroperoxy-6-trans-8,11,14-cis-
eicosatetraenoic acid] and its subsequent transformation to
LTA4. 5-LOX is thought to receive arachidonic acid from the
nuclear membrane–embedded 5-LOX-activating protein
(FLAP). The crystal structure of 5-LOX revealed an ac-
tive site concealed by F177 and Y181 (FY cork). We ex-
amined the influence of the FY cork on 5-LOX activity
and membrane binding in HEK293 cells in the absence
andpresenceofFLAP.Uncapping the5-LOXactive siteby
mutation of F177 and/or Y181 to alanine (5-LOX-F177A,
5-LOX-Y181A, 5-LOX-F177/Y181A) resulted in delayed
and diminished 5-LOX membrane association in A23187-
stimulatedcells.For5-LOX-F177Aand5-LOX-F177/Y181A,
formation of 5-LOX products was dramatically reduced
relative to 5-LOX–wild type (wt). Strikingly, coexpression of
FLAP inA23187-activatedHEK293 cells effectively restored
formation of 5-H(p)ETE (5-hydroxy- and 5-peroxy-6-trans-
8,11,14-cis-eicosatetraenoic acid) by these same 5-LOX mu-
tants (60–70% 5-LOX-wt levels) but not of LTA4 hydro-
lysis products. Yet 5-LOX-Y181A generated 5-H(p)ETE at
levels comparable to5-LOX-wt but reducedLTA4hydrolysis
products. Coexpression of FLAP partially restored LTA4
hydrolysis product formation by 5-LOX-Y181A. Together,
the data suggest that the concealed FY cork impacts
membrane association and that FLAP may help shield
an uncapped active site.—Gerstmeier, J., Newcomer,
M. E., Dennhardt, S., Romp, E., Fischer, J., Werz, O.,
Garscha, U. 5-Lipoxygenase-activating protein rescues
activity of 5-lipoxygenase mutations that delay nuclear
membrane association and disrupt product formation.
FASEB J. 30, 1892–1900 (2016). www.fasebj.org
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The crucial role of leukotrienes (LTs) in nonresolving and
persistent inflammation-related diseases such as asthma
bronchiale and allergic rhinitis expandedwithin the last 30
y to include cardiovascular diseases, cancer, andAlzheimer
disease (1–3). LT biosynthesis from endogenous released
arachidonic acid (AA) is catalyzed by 5-lipoxygenase
(5-LOX) and requires the subcellular redistribution of
soluble 5-LOX to the nuclear membrane–embedded
5-LOX-activating protein (FLAP) for effective AA transfer
(4). Although the structures of both proteins have been
solved, themolecular basis for efficientmetabolismof AA
by 5-LOX in conjunction with FLAP remains elusive.
Lipoxygenases (LOXs) are classified by the stereo- and
regioselectivities with which they oxygenate AA. The active
sites that accommodate AA must position a single specific
pentadiene at the catalytic center, and the register is set by
the depth of the cavity and whether the AA slides in car-
boxyl or methyl end first (5, 6). 5-LOX catalyzes successive
reactions in a single active site. The first AA-converting
reaction is common to all mammalian LOXs and results in
a LOX-specific hydroperoxide of AA. However, 5-LOX
also processes the peroxidation product 5-HPETE [5(S)-
hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid] to
leukotriene A4 (LTA4) in a second catalytic reaction,
the so-called synthase activity (7, 8). This 2-step concerted
reaction is unique for 5-LOX, and the product ratio of
5-H(p)ETE (5-hydroxy- and 5-peroxy-6-trans-8,11,14-cis-
eicosatetraenoic acid) to LTA4 depends on many regula-
tory factors for 5-LOX activity, such as phosphorylation,
protein activation by phosphatidylcholine, ATP, Ca2+
and/or Mg2+ ions, protein–protein interactions, and cellu-
lar compartmentalization (9–11). While 5-H(p)ETE, for-
mation is favored in cell-free assays by high substrate excess
and enzyme concentration (7, 12), LTA4 biosynthesis is
promoted in intact cells upon nuclear membrane binding
(13), and the concomitant association with its AA transfer
protein FLAP appears to play a key role in assuring the
reaction goes to completion (10, 14–16).
Abbreviations: 5-H(p)ETE, 5-hydroxy- and 5-peroxy-6-trans-
8,11,14-cis-eicosatetraenoic acid; 5-HPETE, 5(S)-hydroperoxy-6-
trans-8,11,14-cis-eicosatetraenoic acid; 5-LOX, 5-lipoxygenase; AA,
arachidonic acid; FLAP, 5-lipoxygenase-activating protein; IF,
immunofluorescence; LOX, lipoxygenase; LT, leukotriene; LTA4,
leukotriene A4; PLA, proximity ligation assay; wt, wild-type
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The crystal structure of a stabilized form of human
5-LOX(Stable-5-LOX) revealed a fully encapsulated active
site plugged by the insertion of 2 aromatic amino acids
(F177 and Y181), referred to as the FY cork (17). A corked
active site has been described for a second LOX (18), and
both corked enzymes gain access to their substrates via
Ca2+-dependent membrane binding (19). Recently it has
been shown that substitution of the cork forming residues
by Ala does not compromise 5-H(p)ETE production in a
cell-free assay (20). We asked whether these same amino
acids that blockAAaccess to the encapsulated active site of
5-LOX might be important in a cellular context in con-
junction with FLAP, perhaps to coordinate membrane
binding with unblocking active site access. HEK293 cells
stably transfected for coexpression of FLAP and 5-LOX
mutants weremonitored for 5-LOX nuclear translocation
and for the capacity to generate 5-LOX products. We
found that mutations to the corking amino acids have a
profound effect of 5-LOX translocation to the nuclear
membrane. Strikingly, 5-LOX mutations that resulted in
impaired product formation could be rescued by the
presence of FLAP, and this rescue effect was obviated in
the presence of the FLAP inhibitor MK886. Our data
suggest a model in which the FY cork, which in the struc-
ture is concealed and blocks entrance to the catalytic
machinery, contributes to the nuclearmembrane binding
capacity of 5-LOX. Moreover, the observation that the
coexpression of FLAP with a subset of the 5-LOXmutants
restores 5-LOX–wild-type (wt)-like levels of products
formed in intact cells suggests a physical protein–protein
interaction, beyond colocalization, of 5-LOX and FLAP.
MATERIALS AND METHODS
Materials
DMEM, fetal calf serum, penicillin, streptomycin, trypsin/EDTA,
and geneticin were from PAA Laboratories (Coelbe, Germany).
Lipofectamine LTXReagent Plus, 10%nonimmune goat serum,
Alexa Fluor 488 goat anti-rabbit, Alexa Fluor 555 goat anti-
mouse, Alexa Fluor 488 donkey anti-rabbit, Alexa Fluor 555
donkey anti-goat, DAPI, hygromycin B, and chemically compe-
tent Escherichia coli cells (OneShot Top10) were from Invitrogen
(Carlsbad, CA, USA). The Q5 Site-Directed Mutagenesis kit
(without competent cells) was from New England Biolabs
(Ipswich, MA, USA). Restriction enzymes and GeneJet-plasmid
miniprep kit were from Fermentas (Darmstadt, Germany).
GeneJet-plasmid miniprep kit was from Thermo Scientific
(Darmstadt, Germany). The mouse anti-5-LOX monoclonal
antibody was the gift of D. Steinhilber (Goethe University
Frankfurt, Germany) and rabbit anti-5-LOX polyclonal an-
tibody was supplied by O. Rådmark (Karolinska Institutet,
Stockholm, Sweden). The rabbit anti-FLAP polyclonal antibody
and goat anti-FLAP polyclonal antibody were from Abcam
(Cambridge, MA, USA). Mouse anti-b-actin monoclonal anti-
body was from Santa Cruz (Heidelberg, Germany). MK886 was
from Cayman Chemicals (Ann Arbor, MI, USA) and zileuton
from Sequoia Research Products (Oxford, United Kingdom).
Mowiol was from Calbiochem (Bad Soden, Germany). Poly-D-
lysin-coated glass coverslips were from neuVitro (El Monte, CA,
USA). HPLC solvents were fromMerck (Darmstadt, Germany).
AA, Ca2+-ionophoreA23187, prostaglandin B1, dNTPs, Duolink
detection reagents red, Duolink proximity ligation assay (PLA)
probe anti-rabbit Plus, Duolink PLA probe anti-mouse Minus,
Duolink PLA probe anti-goat Minus as well as Duolink wash
buffers, and all other chemicals were from Sigma-Aldrich (Dei-
senhofen, Germany) unless stated otherwise.
Cells
HEK293 cells were cultured at 37°C and 5% CO2 in DMEM
containing 10% heat-inactivated fetal calf serum, 100 U/ml
penicillin, and 100mg/ml streptomycin as monolayers. Cell lines
stably expressing 5-LOX (wt and mutants) and/or FLAP were
selected by 400 mg/ml geneticin and/or 200 mg/ml hygromycin
B as described elsewhere (15).
Site-directed mutagenesis
The pcDNA3.1_5-LOX vector was used as a template for ampli-
fication of the 5-LOX-wt coding sequence. Mutations were in-
troduced with the Q5 Site-Directed Mutagenesis kit (New
England Biolabs) according to the manufacturer’s instruc-
tions, and oligonucleotides of;30 bases were ordered by Tib
Molbiol. All constructs were confirmed by sequencing.
Stable expression in HEK293
Transfection of HEK293 cells with pcDNA3.1/neom (+)_5-LOX-
wt or mutants, and pcDNA3.1/Hygro (2)_FLAP was performed
as described before after selection with antibiotics (15). Stable
expressing colonies were verifiedby immunoblotting andassayed
for 5-LOX activity.
Determination of 5-LOX product formation in transfected
HEK293 cells
HEK293 cells were collected by trypsinization and centrifugation
(1200 rpm, 10 min, 4°C). 5-LOX product synthesis in intact cells
stably expressing 5-LOX-wt or 5-LOX mutants with and without
FLAP was determined as previously described (15). In brief, 13
106 cells in 1 ml PGC buffer (PBS, 0.1% glucose, and 1 mM
CaCl2) were stimulated with 2.5 mM A23187 plus 3 mM exoge-
nous AA for 10 min at 37°C. The reaction was stopped by ad-
dition of 1ml ice-coldmethanol. Upon the addition of acidified
PBS plus internal standard (200 ng prostaglandin B1), 5-LOX
products (all-trans isomers of LTB4 and 5-H(p)ETE) were
extracted using C18 columns (100 mg; United Chemical
Technologies, Bristol, PA, USA) and analyzed by reverse-phase
HPLC using the C-18 Radial-PAK column (Waters, Eschborn,
Germany) as previously described (21).
5-LOX product formation was also determined in crude
HEK293 cell homogenates. Cells were collected andresuspended
in PBS containing 1mMEDTA.Homogenization was reached by
sonication for 33 10 s at 4°C. Samples (corresponding to 13 106
cells/ml) were preincubated with inhibitors or vehicle (0.1%
DMSO) at 4°C for 15 min before addition of 2 mM CaCl2 and
stimulationwith 3mMAA. 5-LOXmetabolites were extracted and
analyzed as stated above for intact cells.
Subcellular localization by immunofluorescence microscopy
HEK293 cells expressing 5-LOX-wt or 5-LOXmutants without or
together with FLAP were seeded on poly-D-lysine-coated glass
coverslips and cultured at 37°C until ;60% confluence, as de-
scribed previously (21). Cells were stimulated with 2.5 mM
A23187 for the indicated time points at 37°C and fixed by 4%
paraformaldehyde solution. Fixation-induced autofluorescence
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was reduced by addition of 50 mM ammonium chloride. Cells
were permeabilized with 100% acetone (4°C, 5 min) and 0.25%
Triton-X (room temperature, 10 min). Primary antibodies
(mouse monoclonal anti-5-LOX 1:1000 or rabbit polyclonal
anti-5-LOX for the 5-LOX-F177/Y181A mutant 1:500; rabbit
polyclonal anti-FLAP 1:500 or goat polyclonal anti-FLAP 1:100)
diluted in blocking solution (10% nonimmune goat serum)
were added overnight at 4°C. Fluorophore-labeled secondary
antibodies Alexa Fluor 488 goat anti-rabbit (1:500) and Alexa
Fluor 555 goat anti-mouse (1:500), or Alexa Fluor 488 donkey
anti-rabbit (1:1000) andAlexaFluor555donkey anti-goat (1:1000)
were applied in the dark (20 min, room temperature) after in-
tensive washing with PBS. DAPI (0.1 mg/ml) was used for DNA
staining. Coverslips were mounted on glass slides with mowiol
containing 2.5% n-propyl-gallate. Samples were analyzed with a
Zeiss Axiovert 200M microscope and a Plan Neofluar 340/1.30
Oil (DIC III) objective (Carl Zeiss, Jena, Germany). An AxioCam
MR camera (Carl Zeiss) was used for image acquisition.
In situ analysis of 5-LOX/FLAP interaction by proximity
ligation assay
PLA was performed according to the manufacturer’s protocol to
analyze in situ interaction between 5-LOX and FLAP (22). In
brief, cells were treated and fixed as described above for immu-
nofluorescence (IF) microscopy. Species specific secondary an-
tibodies conjugated to oligonucleotides (PLA probe anti-mouse
Minus/anti-rabbit Plus or anti-goat Minus/anti-rabbit Plus) were
applied for 1 h at 37°C to the samples. After a ligation step (30
min, 37°C) the antibody-bound oligonucleotides formed a DNA
circle. The generated DNA circle was amplified by rolling-circle
amplification and hybridization with fluorescently labeled nu-
cleotides for 100 min at 37°C. Nuclear DNA was stained with
DAPI. PLA signals appearing as red fluorescent spots were de-
tected with an Axiovert 200Mmicroscope (Carl Zeiss) and a Plan
Neofluar 340/1.3 Oil (DIC III) objective (Carl Zeiss). Pictures
were taken with an AxioCam MR camera (Carl Zeiss).
SDS-PAGE and Western blot analysis
For 5-LOX a 10% and for FLAP a 16% polyacrylamide gel was
used for separation. Crude cell lysates were blotted onto nitro-
cellulose membranes (Hybond ECL; GE Healthcare, Freiburg,
Germany). The membranes were incubated with primary anti-
bodies (rabbit anti-5-LOX1:1000, rabbit anti-FLAP 0.1mg/ml, and
mouse anti-actin 1:1000). Subsequently, IR-Dye 800CW-labeled
anti-rabbit or anti-mouse antibodies were used for detection (1:
10,000). The immunoreactive bands were illustrated using an
Odyssey infrared imager (Li-Cor Biosciences, Lincoln, NE,
USA).
Statistical analysis
Results are expressed as means6 SEM of n observations, where n
represents the number of experiments performed at different
days in duplicates unless stated otherwise. Graphs were prepared
with GraphPad Prism 4 software and validated with GraphPad
InStat (GraphPad Software, La Jolla, CA, USA). Student’s t test
was applied for evaluation. A value of P , 0.05 was considered
statistically significant.
RESULTS
The crystal structure of Stable-5-LOXrevealed a concealed
active site, and the bulky amino acid side chains of F177
and Y181 (Fig. 1A,B) appeared to cork the substrate access
portal (17). The results of experiments performed with
purified Stable-5-LOX and site-directedmutant variants in
cell-free assays were consistent with the FY cork serving as a
portal that must reposition to allow substrate to access the
catalytic machinery (20). Here we asked whether in intact
cells, where 5-LOX is subject to regulation by several co-
factors, phosphorylation events, interacting proteins, and
nuclear membrane binding for substrate acquisition (4),
active site access via the corked portal is coordinated with
5-LOX membrane binding in conjunction with FLAP.
HEK293 cells, which are essentially devoid of 5-LOX and
FLAP (15), were stably transfected with the cDNAs
encoding 5-LOX-wt or 5-LOX mutant enzymes where the
bulky amino acids F177 and/or Y181 were substituted, to-
gether and without the cDNA encoding FLAP (15). Both
F177 and Y181were each substitutedwithAla to pare down
the cork volume, and the double mutant F177/Y181A was
prepared to confer accessibility to an otherwise sheltered
cavity. On the basis of the X-ray structure of Stable-5-LOX
(17), replacement of both residues should result in un-
obstructed access and egress to and from the 5-LOX active
site (Fig. 1). Y181 was additionally replaced by Phe to in-
vestigate the possibility that the hydroxyl group of Y181
provides an H bond necessary for catalysis. It has been
reported that in the context of Stable-5-LOX, neither
F177A, Y181A, nor F177/Y181A mutations destabilize the
enzyme and do not adversely affect the basal levels of 5-H
(p)ETE production of purified 5-LOX (in the absence of
cellular regulatory cofactors) (20). Expression of 5-LOX
and FLAP in each of the HEK293 cell lines was verified by
immunoblotting, with normalization to b-actin (Fig. 2).
Variations in the protein expression can be due to site-
directed mutagenesis of 5-LOX that alter the recognition
of the protein by the 5-LOX antibody and thus the in-
tensities of the signal.Weobserved suchdifferences for the
5-LOX-F177/Y181A mutant.
Figure 1. Substrate access to active site of 5-LOX is blocked by
aromatic side chains of F177 and Y181. A) Surface rendering
(white contours) of Stable-5-LOX in which internal cavity at
active site Fe2+ (red sphere) is apparent. For reference, stick
renderings of F177 and Y181, along with 2 histidines that
position Fe2+ in active site, are included (C, magenta; N, blue;
O2, red). AA (gray) as positioned in structure of abortive LOX:
AA complex of 8R-LOX is included to indicate common tubular
U-shaped site observed for LOX with open access cavities. B)
Open access cavity of 15-LOX-2 (light blue contours) overlaid
with 5-LOX amino acids and 8R-LOX substrate.
1894 Vol. 30 May 2016 GERSTMEIER ET AL.The FASEB Journal x www.fasebj.org
FY cork residues influence 5-LOX nuclear membrane
association, colocalization with FLAP, and 5-LOX/
FLAP interaction
Because 5-LOX translocation and association with the
nuclear membrane is a prerequisite for 5-LOX to access
releasedAA via transfer by FLAP (4), wefirst investigated if
mutations of the FY cork might affect 5-LOX nuclear
membrane association upon cell activation by using IF
microscopy. In agreement with our prior findings (15),
resting HEK293 cells expressing 5-LOX-wt and FLAP
revealed a homogenous intranuclear staining of 5-LOX.
Upon A23187 activation, 5-LOX rapidly (within 90 s)
translocated to the nuclear membrane and colocalized
with FLAP (Fig. 3). Overall, replacement of Y181 or F177
caused a delayed accumulation of themutated 5-LOXs at
the nuclear membrane compared to wt enzyme (Fig. 3).
This observation was more pronounced for the double
mutant (5-LOX-F177/Y181A), in which it took up to 10
min to detect distinct association at the nuclear mem-
brane and colocalization with FLAP (Fig. 3). Parallel IF
experiments with cells lacking FLAP (data not shown)
also showed defective translocation of 5-LOXmutants to
the nuclear membrane upon stimulation, while trans-
location of 5-LOX-wt was again unaltered (15).
While IF microscopy is able to reveal colocalization of
5-LOX and FLAP, the proximity ligation assay (PLA)
provides a more quantitative view and sets the distance
between the interactingpartners at amaximumof 40nm,
as described before (22). In unstimulated HEK293 cells,
no PLA signal was detected as a result of the absence of
5-LOX/FLAP proximity, regardless of the nature of 5-LOX
(wt or mutated enzymes; Fig. 4). For cells expressing
5-LOX-wt and FLAP, an in situ interaction was detected as
early as 90 s after A23187 stimulation, and the intensity of
the PLA signal increased up to 30 min (Fig. 4).
In agreement with the delayed translocation and
colocalizationof 5-LOXmutantswith FLAP visualizedby IF
(Fig. 3), mutations within the FY cork of 5-LOX resulted in
a delayed 5-LOX/FLAP proximity signal (Fig. 4, red dots).
While for 5-LOX-Y181F or 5-LOX-Y181A only a minor de-
lay in the interaction with FLAP was apparent, in cells
expressing 5-LOX-F177A or the double mutant 5-LOX-
F177/Y181A the formationof a 5-LOX/FLAPcomplexwas
not detectable until 30 min after cell activation, and the
signal intensity was low compared to 5-LOX-wt (Fig. 4).
Together, the data indicate that the FY cork, which con-
ceals the 5-LOX active site, is decisive for rapid association
of 5-LOX with the nuclear membrane and its interaction
with FLAP. Deficient translocation and association could
reflect a loss of affinity for the lipid bilayer, the 5-LOX
protein binding partner FLAP, or both.
Impact of cork mutations on 5-LOX product synthesis
5-LOX product synthesis was analyzed in intact cells upon
activation with 2.5 mM A23187 plus 3 mM AA as well as in
corresponding cell homogenates. According to results
from previous studies, the major 5-LOX products under
these conditions comprise 5-H(p)ETEand trans isomersof
LTB4 (15). 5-LOXactivity in crude homogenates, in which
5-LOX/FLAP interactioncannotbe recapitulated(15, 23),
essentially reflects the amount of catalytically active 5-LOX
proteinand thus is indicative for the level of expressionand
the enzymatic capacity of the respective 5-LOX.Compared
to 5-LOX-wt, mutation of Y181 to Phe or Ala reduced
5-LOX product formation in crude cell homogenates by
roughly 50%. Notably, replacement of F177 by Ala almost
completely abolished 5-LOX activity in homogenates
(Table 1) despite comparable protein expression (Fig. 2).
As expected, the presence of FLAP in homogenates of
coexpressing cells caused no significant modulation of
activity (Table 1). In intact cells devoid of FLAP, re-
placement of Y181 by Phe or Ala caused no marked dif-
ferences in total 5-LOX product formation vs. 5-LOX-wt
(Table 1). In contrast, mutation of F177 to Ala (5-LOX-
F177A and 5-LOX-F177/Y181A) strongly reduced 5-LOX
activity, and only trace levels of 5-LOX products (4.06 0.9
and 4.6 6 1.1 ng/106 cells, respectively) were formed.
Strikingly, coexpression of FLAP significantly increased
cellular product formation of all (wt andmutants) 5-LOXs
in intact HEK293 cells (Table 1). Thus, in the presence of
FLAP, the amounts of products formed by 5-LOX-Y181F
and 5-LOX-Y181A (153.96 12.4 and 176.56 12.8 ng/106
cells) were comparable to those generated by 5-LOX-wt/
FLAP (170.0 6 2.4). Remarkably, coexpression of FLAP
increased the low product levels of F177A-mutant enzymes
(i.e., 5-LOX-F177A or 5-LOX-F177/Y181A) by 25- and
17-fold (Table 1), suggesting that in intact cells FLAP ef-
fectively rescued the impairedactivityof theF177Amutants.
For instance, cells expressing 5-LOX-F177A produced only
4.06 0.9ng 5-LOXproducts per 106 cells, butwhenFLAP
is coexpressed, 99.66 16.0 ng 5-LOXproducts per 106 cells
were formed. Note that the same cells, 5-LOX-F177A/
FLAP, generated only 8.1 6 0.9 ng products in crude ho-
mogenates corresponding to 106 cells (Table 1), indicating
that the rescuing action of FLAP is exclusively operative in
intact cells.
FY cork affects FLAP-mediated LTA4 and
5-HPETE formation
As mentioned above, 5-LOX catalyses 2 reactions in the
transformation of AA. First, the oxygenase activity yields
the intermediate 5-HPETE, which is dehydrated by the
second reaction, synthase activity to LTA4, and both con-
versions are promoted by FLAP, although to a different
extent (10, 15). Because FLAP facilitated the product
synthesis of wt- and mutated 5-LOXs in HEK293 cells, we
investigated the stimulatory effect of FLAP on the AA
Figure 2. Expression of 5-LOX-wt and mutants with and
without FLAP in HEK293. Protein levels of 5-LOX-wt or
mutants (top) and FLAP (middle) were analyzed by Western
blot analysis, normalized to b-actin (bottom). Results are
representative of at least 3 independent experiments.
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metabolite profile [5-H(p)ETE vs. LTA4 hydrolysis prod-
ucts]. For 5-LOX-wt, coexpressionofFLAPslightly elevated
5-H(p)ETE synthesis but strongly increased formation of
LTA4 hydrolysis products in intact cells, as the presence of
FLAP seems to help the reaction go to completion (15). In
the absence of FLAP, 5-LOX-Y181F or 5-LOX-Y181A pro-
duced little LTA4 metabolites compared to 5-LOX-wt
(Table 2). In fact, 5-LOX-Y181F produced 11.3 timesmore
5-H(p)ETE than LTA4, whereas in FLAP coexpressing
cells, the ratio of 5-H(p)ETE vs.LTA4was reduced to 3.3 as
a result of elevated levels of LTA4 without effecting 5-H(p)
ETE levels. Similarly, for cells expressing5-LOX-Y181A, the
synthesis ofLTA4metaboliteswasnearly 3-fold increased in
the presence of FLAP. Thus, FLAP may fully compensate
for the detrimental effects of the Y181 mutation to Phe in
5-LOX-Y181F but only partially restores the impairedLTA4
synthesis of 5-LOX-Y181A,perhapsbecause the smallAla at
this position allows the intermediate 5-HPETE to leak out
of the active site, even in the presence of FLAP. HEK293
cells expressing 5-LOXmutants where F177 is replaced by
Ala (i.e., 5-LOX-F177A or 5-LOX-F177/Y181A) did not
produce detectable amounts of LTA4metabolites, and 5-H
(p)ETE formation was drastically impaired (Table 2).
Coexpression of FLAP partially, but only slightly, restored
the capacity to produce LTA4 in 5-LOX-F177A cells
(Table 2), whereas 5-LOX-F177/Y181A failed to produce
detectable LTA4 hydrolysis products even in the presence
of FLAP (Table 2). However, FLAP efficiently increased
5-H(p)ETEsynthesis forbothF177-mutated5-LOXenzymes
(Table 2).
In cell-free assays analyzing the corresponding homog-
enates of the cell lines, 5-LOX-wt produced about twice as
much 5-H(p)ETE vs. LTA4 hydrolysis products (Fig. 5)
(15). As in intact cells, 5-LOX-Y181F and 5-LOX-Y181A
scarcely produced LTA4 metabolites despite substantial
formation of 5-H(p)ETE (Fig. 5), suggesting that Y181may
play a critical role in the synthase activity, which may
require retention of the intermediate in the active site.
Figure 3. Time-resolved subcellular localization of 5-LOX-wt and mutants in FLAP coexpressing HEK293. Localization of 5-LOX-
wt (top) and 5-LOX mutants (as designated) upon stimulation with A23187 (2.5 mM) for indicated time points was monitored by
indirect IF microscopy. Cells were fixed, permeabilized, and incubated with antibodies against 5-LOX (Alexa Fluor 555, red) and
FLAP (Alexa Fluor 488, green). Images show overlay of staining for 5-LOX and FLAP. Results are representative of 100 individual
cells of 3 independent experiments. Scale bar, 30 mm.
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5-LOX-F177A and 5-LOX-F177/Y181A produced exclu-
sively 5-H(p)ETE in cell homogenates, though to a very
minor degree (Fig. 5). As expected, FLAP did not signifi-
cantly alter the amounts or product profiles in the cell-free
assay for either 5-LOX-wt or mutant variants (Fig. 5).
Together, the detrimental effects of Y181 mutation on
5-LOX product synthesis (oxygenase and synthase activity)
in intact cells can be reversed by coexpression of FLAP,
while for the F177 mutation only, 5-H(p)ETE synthesis
(oxygenase activity) can be restored by FLAP.
TABLE 1. Amounts of 5-LOX products (ng/106 cells) formed in intact HEK293 cells and
corresponding homogenates without and with FLAP upon stimulation with 2.5 mM A23187
plus 3 mM AA
5-LOX
Homogenates Intact cells
No FLAP FLAP No FLAP FLAP
wt 241.7 6 26.4 234.1 6 21.7 97.6 6 6.3 170.0 6 2.4***
Y181F 135.5 6 13.0 145.0 6 33.6 76.6 6 13.5 153.9 6 12.4**
Y181A 107.3 6 31.9 122.4 6 18.6 123.2 6 13.2 176.5 6 12.8*
F177A 5.8 6 0.9 8.1 6 0.9 4.0 6 0.9 99.6 6 16.0***
F177/Y181A 6.1 6 0.7 10.7 6 1.5 4.6 6 1.1 78.2 6 11.8***
Data are provided as means 6 SEM; n = 4, duplicates. ***P , 0.001; intact cells with FLAP vs. intact
cells with FLAP, Student’s t test.
Figure 4. Time-resolved in situ protein–protein interaction of 5-LOX-wt and mutants with FLAP. In situ PLA, using proximity
probes against 5-LOX and FLAP, was performed in designated cell lines upon stimulation with A23187 (2.5 mM) for indicated
time points. DAPI (blue) was used to stain nucleus, and in situ PLA signals (red dots) visualize 5-LOX/FLAP interaction. Scale
bar, 50 mm. Results are representative of 100 individual cells analyzed in 3 independent experiments.
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MK886 selectively antagonizes the FLAP-mediated
increase of 5-LOX product formation
Studies with the FLAP antagonist MK886 were per-
formed in intact cells to address whether the effect of FLAP
coexpression is directly related to its role as the AA delivery
protein partner for 5-LOX. For 5-LOX-wt, MK886 (30 nM)
antagonized the FLAP-mediated increase in 5-LOX prod-
uct formation down to the levels of products formed by
cells devoid of FLAP, whereas in the latter cellsMK886was
without any effect, as described recently (15). Along these
lines, MK886 (30 nM) effectively abolished the marked
FLAP-mediated increase in cellular product synthesis of
5-LOX-F177A and 5-LOX-F177/Y181A (Fig 6). For cells
expressing 5-LOX-Y181A or 5-LOX-Y181F, the increased
LTA4 synthesis via FLAP was repressed by 30 nM MK886.
These data are consistent with a functional and direct effect
of FLAP coexpression on 5-LOX-wt and mutant activities.
DISCUSSION
5-LOX has a unique structural motif that blocks access to
the catalytic iron, an aromatic cork that closes off what has
been described as an accessible tubular, U-shaped active
site in homologous LOXs. The catalytic iron is positioned
at the base of the U, which in 15-LOX-2, the closest 5-LOX
homolog for which a structure is available, is deep enough
to accommodate AA, the 20-carbon substrate. We asked
whether in intact cells this corking motif might be impor-
tant in the transfer of substrate from FLAP to 5-LOX. Re-
markably, we observed that mutations to the corking
residues,whichare concealed in theactive site in thecrystal
structure, are crucial for 5-LOX association with the nu-
clear membrane in the cell. Studies on the purified
recombinant 5-LOX enzyme where the aromatic corking
amino acids F177 and Y181 are substituted by Ala demon-
strate that removal of the bulky cork does not adversely
affect the capacity to oxygenate free AA of Stable-5-LOX
(20), an engineered 5-LOX that harbors multiple substi-
tutions to confer stability and removemembrane insertion
loops that might promote aggregation (17). Yet in a cel-
lular context, when expressed in the absence of FLAP,
these same mutations in 5-LOX lead to a reduction in the
amount of 5-LOX products analyzed, whether from intact
cells or cell homogenates. Under these conditions, stimu-
lating factors such as phospholipids, Ca2+, and ATP (4)
would be present, and 5-LOX-wt activity is likely to reflect
this stimulation.
5-LOX membrane association with the lipid bilayer is
governed by key amino acids in the N-terminal b-barrel
domain, including W13, W75, and W102 (24–26). More
recent results have demonstrated a membrane binding
activity by a catalytic domain fragment lacking the
N-terminalb-barrel (27).We observed that F177 and Y181,
amino acid side chains concealed in the active site and
distal to the N-terminal membrane binding domain, are
crucial for 5-LOX association to the nuclear membrane.
This observation suggests that either these concealed
amino acids interact with the lipid bilayer or that the im-
paired nuclear translocation is a consequence of a con-
formational change provoked by a mutation that is
incompatible with membrane binding. Although we can-
not eliminate the second possibility, the same substitutions
werenot destabilizing in the Stable-5-LOX(20).Moreover,
there is substantial precedent for membrane anchoring
of proteins by the insertion of aromatic amino acid side
chains into the bilayer. In transmembrane proteins, Tyr is
often located at the bilayer interface, while Phe can be
found throughout the bilayer (28, 29). In addition, mono-
topic membrane proteins such as cyclooxygenase (30) and
phospholipase C (31) have been shown to be anchored in
part by aromatic amino acid interactions with the bilayer.
TABLE 2. Amounts of 5-H(p)ETE and trans isomers of LTB4, given as ng/10
6 cells in intact HEK293 cells of 5-LOX-wt and mutants without
and with FLAP coexpression of FLAP after cell activation with 2.5 mM A23187 and 3 mM AA
5-LOX
No FLAP FLAP
5-H(p)ETE (t)LTB4 5-H(p)ETE/(t)LTB4 5-H(p)ETE (t)LTB4 5-H(p)ETE/(t)LTB4
wt 83.2 6 5.3 14.5 6 1.0 5.8 113.4 6 0.6 56.6 6 3.0 2.0
Y181F 71.2 6 12.9 5.4 6 1.2 13.1 118.4 6 9.4 35.6 6 4.3 3.3
Y181A 117.3 6 12.3 5.8 6 1.0 20.1 162.2 6 11.9 14.3 6 1.0 11.3
F177A 4.0 6 0.9 — — 98.5 6 16.0 1.1 6 0.2 91.4
F177/Y181A 4.6 6 1.1 — — 78.2 6 11.8 — —
Data are provided as means 6 SEM; n = 4, duplicates.
Figure 5. Influence of FLAP on product profile of 5-LOX-wt
or mutants in homogenates. (A) Amounts of 5-H(p)ETE (solid
bars) and trans isomers of LTB4 (open bars) in nanograms per
106 cells in crude cell homogenates of 5-LOX-wt and mutants
with or without FLAP were measured upon incubation with 1
mM CaCl2 and 3 mM AA for 10 min at 37°C. Data are expressed
as means 6 SEM; n = 4, duplicates.
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Cells expressing 5-LOX variants that display delayed
accumulation at the nuclear membrane were evaluated in
terms of product formation. Strikingly, the presence of
FLAP increased 5-LOX product levels in intact cells (but
not in crude cell homogenates) that in return was abol-
ished by the FLAP inhibitor MK886. For the Y181A and
Y181F 5-LOXmutants in the presence of FLAP, the levels
observed were comparable to those of 5-LOX-wt. More-
over, increased amounts of LTB4 isomers were observed
under these conditions. It was previously shown that the
presence of FLAP increases the probability that 5-LOX
completes the 2-step reaction (an increase in LTA4 rela-
tive to H(p)ETE), suggesting that FLAP protects 5-LOX
from premature loss of the intermediate HPETE (15). The
observation that FLAP rescues the 5-LOX mutants with im-
paired activities and results in product levels comparable to
5-LOX-wt is suggestive of a physical interaction between the
protein partners, which in part helps restore a functional
conformation to 5-LOX. A less specific, secondary effect of
FLAP coexpression, such as a membrane perturbation (not
detectable in these experiments) that promotes 5-LOX
membrane association, seems unlikely given that the FLAP
inhibitor MK886 at a low concentration of only 30 nM ab-
rogates the rescue effect of FLAP. Moreover, because our
data suggest the involvement of F177 and Y181 in 5-LOX
nuclear membrane binding, thereby opening the entrance
of the substratecavity, it seemsunlikely that these residuesare
also involved in the dimer formation. In fact, the interface
mediating 5-LOX dimerization is suggested to be formed by
cysteine residues at the surface of the 5-LOX protein (32).
In summary, IF andPLAdata reveal a significant effect of
the substitution of F177 and Y181, both residues buried in
the 5-LOX active site, and demonstrate a compromised
5-LOX nuclear membrane association and 5-LOX/FLAP
interaction.Despite this impairment,which leads to adelay
in the detection of the mutants at the nuclear membrane
by either IF orPLA, theproteins are still able to reachFLAP
and gain access to substrate, as evidencedby the fact that in
intact cells, the presence of FLAP improves product yields.
The dramatic impact of FLAP on product yields suggest a
physical protein–protein interaction between 5-LOX and
FLAP and that a productive, functional interaction does
not require either F177 or Y181. However, these same
aminoacidsmayhelpprolong the transient protein–protein
coupling that must occur during the course of the 2-step
reaction, either by providing an additional contact with the
bilayer, by FLAP, or by both. While previous studies clearly
demonstrated the proximity of 5-LOX and FLAP at the nu-
clear membrane (33–35), the molecular details of this in-
teraction, which are clearly complex, given that a 5-LOX/
FLAP interaction in cell homogenates has yet to be dem-
onstrated, remain to be elucidated.Our results define a role
for the aromatic cork, buried in the active site of 5-LOX in
the absence of substrate, in stabilizing a 5-LOX/FLAP in-
teraction in intact cells.
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B., and Rådmark, O. (2014) Roles of coactosin-like protein (CLP)
and5-lipoxygenase-activatingprotein (FLAP) in cellular leukotriene
biosynthesis. Proc. Natl. Acad. Sci. USA 111, 11371–11376
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